Justin Oldham
Associate Professor of Internal Medicine
Medical School
Office:
University of Michigan
1150 W. Medical Center Drive MSRBIII
Ann Arbor, Michigan 48109
1150 W. Medical Center Drive MSRBIII
Ann Arbor, Michigan 48109
Email:
[email protected]
Available to mentor
Justin Oldham
Associate Professor
Manage Your Profile
About
I am a pulmonary fibrosis specialist and director of the UM ILD program. As a PhD Epidemiologist and translational physician scientist, I conduct research aimed at developing blood-based biomarkers to accurately predict pulmonary fibrosis progression and treatment response.
Qualifications
-
FellowshipUniversity of Chicago, Chicago, United States
2011 - 2016
Postdoctoral Fellowship
-
ResidencyUniversity of California at Davis, USA
2006 - 2009
Residency
-
PhDUniversity of Michigan Medical School, Ann Arbor, United States
2022 - 2025
-
M.S.University of Chicago, United States
2014 - 2016
-
M.D., MedicineUniversity of Colorado, United States
2002 - 2006
-
B.A., HistoryUniversity of Colorado, United States
1997 - 2002
Center Memberships
-
Center MemberAI and Digital Health Innovation
Research Overview
Pulmonary fibrosis, proteomics, biomarkers, Epidemiology
Recent Publications
-
Oldham JM, Neely ML, Wojdyla DM, Antao VC, Todd JL. Future Rare Diseases, 2026 Mar 12; 6 (1):Journal ArticleDecline in lung function increases the risk of death in patients with idiopathic pulmonary fibrosis: a plain language summary
DOI:10.1080/23995270.2026.2635365 -
2026 Apr 13;PresentationPredicting ILD Progression with Precision
-
Zhyvylo I, Sood N, Pugashetti JV, Linderholm AL, Hsu SW, Oldham J, Chen CH, Goncharova EA. Pulmonary Circulation, 2026 Sep 1; 16 (3):Journal ArticleSmoking-Related Clinical and Molecular Abnormalities in Idiopathic Pulmonary Fibrosis—Associated Pulmonary Hypertension
DOI:10.1002/pul2.70349 -
Podolanczuk AJ, Drake WP, Maher TM, Martinez FJ, Oldham JM, Sime PJ, Luo F. Am J Respir Crit Care Med, 2026 Aug 17;Journal ArticleFrom Mechanisms to Clinical Practice: Introduction to an AJRCCM Special Section on Interstitial Lung Disease.
DOI:10.1093/ajrccm/aamag433 PMID: 42608799 -
Kim JS, Adegunsoye A, Ma S-F, Huang Y, Paul TK, Strek ME, Chung JH, Oh A, Martinez FJ, Oldham JM, Lynch DA, Noth I, Humphries SM. ERJ Open Research, 2026 Aug 17; 00290 - 02026.Journal ArticleQuantitative computed tomography improves prediction of survival across ILD subtypes
DOI:10.1183/23120541.00290-2026 -
Wang JM, Pugashetti JV, Thompson J, Kang E, Kazerooni EA, Flaherty KR, Belloli EA, Sheth JS, O'Dwyer DN, Han MK, Hatt CR, Oldham JM, Chung JH. Chest, 2026 Aug 12;Journal ArticleSurvival According to Radiomic and Visual UIP Classification in Fibrotic ILD.
DOI:10.1016/j.chest.2026.08.002 PMID: PMC13494922 -
Oldham JM, Zoz DF. Am J Respir Crit Care Med, 2026 Aug 6;Journal ArticleReply to Jiang: When a Key Composite Endpoint Is Neutral: Should Mortality Trends Drive Interpretation?
DOI:10.1093/ajrccm/aamag415 PMID: 42560853 -
Oldham JM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold A-M, Kreuter M, Maher TM, Richeldi L, Valenzuela C, Wijsenbeek MS, Choy S, Gu H, Weimann G, Ritter I, Stowasser S, Zoz DF, Martinez FJ. Eur Respir J, 2026 Jul 30;Journal ArticleEffect of nerandomilast on survival in patients with pulmonary fibrosis.
DOI:10.1183/13993003.00338-2026 PMID: 42532543
Featured News & Stories
Department News
CME Event - Updates in the Diagnosis and Treatment of Interstitial Lung Disease
Join University of Michigan experts on Tuesday, January 27, 2026 from 2-3 pm for a free virtual panel discussion on the current updates in the diagnosis and treatment of interstitial lung disease.
